[Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation].
In our facility, three patients developed tacrolimus (TAC)-induced renal dysfunction after allogeneic hemopoietic stem cell transplantation, although trough levels of TAC were within therapeutic ranges. They received an oral agent of slow-release TAC once a day instead of a regular form oral TAC twice a day. Following treatment with the prolonged-release agent, serum creatinine levels decreased and graft-versus-host disease (GVHD) did not occur. Use of this slow-release formulation may avoid toxic peak concentrations of TAC without the development of GVHD.
Division of Cell Therapy, Jichi Medical University Hospital.
Rie
R
Hosonuma
Shin-Ichiro
S
Fujiwara
Miyuki
M
Sasazaki
Yuji
Y
Hirata
Chihiro
C
Yamamoto
Mitsuyo
M
Uesawa
Iekuni
I
Oh
Tomohiro
T
Matsuyama
Masaki
M
Mori
Keiya
K
Ozawa
Kazuo
K
Muroi
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000517:prevention & control*; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D007166:Immunosuppressive Agents; D016559:Tacrolimus